Literature DB >> 24378326

Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in mice.

Matthew D Merrell1, Beatrice A Nyagode, John D Clarke, Nathan J Cherrington, Edward T Morgan.   

Abstract

Various disease models have been shown to alter hepatic drug-metabolizing enzyme (DME) and transporter expression and to induce cholestasis through altered enzyme and transporter expression. Previously, we detailed the regulation of hepatic DMEs during infectious colitis caused by Citrobacter rodentium infection. We hypothesized that this infection would also modulate hepatic drug transporter expression and key genes of bile acid (BA) synthesis and transport. Mice lacking Toll-like receptor 4 (TLR4), interleukin-6 (IL-6), or interferon-gamma (IFNγ) and appropriate wild-type animals were orally infected with C. rodentium and sacrificed 7 days later. In two wild-type strains, drug transporter mRNA expression was significantly decreased by infection for Slc22a4, Slco1a1, Slco1a4, Slco2b1, and Abcc6, whereas the downregulation of Abcc2, Abcc3, and Abcc4 were strain-dependent. In contrast, mRNA expressions of Slco3a1 and Abcb1b were increased in a strain-dependent manner. Expression of Abcb11, Slc10a1, the two major hepatic BA transporters, and Cyp7a1, the rate-limiting enzyme of BA synthesis, was also significantly decreased in infected animals. None of the above effects were caused by bacterial lipopolysaccharide, since they still occurred in the absence of functional TLR4. The downregulation of Slc22a4 and Cyp7a1 was absent in IFNγ-null mice, and the downregulation of Slco1a1 was abrogated in IL-6-null mice, indicating in vivo roles for these cytokines in transporter regulation. These data indicate that C. rodentium infection modulates hepatic drug processing through alteration of transporter expression as well as DMEs. Furthermore, this infection downregulates important genes of BA synthesis and transport and may increase the risk for cholestasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24378326      PMCID: PMC3965897          DOI: 10.1124/dmd.113.055525

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  40 in total

Review 1.  Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.

Authors:  Alexander M Cressman; Vanja Petrovic; Micheline Piquette-Miller
Journal:  Expert Rev Clin Pharmacol       Date:  2012-01       Impact factor: 5.045

2.  Characterization of organic anion-transporting polypeptide (Oatp) 1a1 and 1a4 null mice reveals altered transport function and urinary metabolomic profiles.

Authors:  Lei Gong; Nelly Aranibar; Yong-Hae Han; Youcai Zhang; Lloyd Lecureux; Vasanthi Bhaskaran; Purnima Khandelwal; Curtis D Klaassen; Lois D Lehman-McKeeman
Journal:  Toxicol Sci       Date:  2011-05-10       Impact factor: 4.849

3.  Selective role for tumor necrosis factor-α, but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen.

Authors:  Ryan D Kinloch; Choon-Myung Lee; Nico van Rooijen; Edward T Morgan
Journal:  Biochem Pharmacol       Date:  2011-05-06       Impact factor: 5.858

Review 4.  Cholestasis and the role of basolateral efflux pumps.

Authors:  D Keppler
Journal:  Z Gastroenterol       Date:  2011-12-02       Impact factor: 2.000

5.  Regulation of drug transporter mRNA expression by interferon-γ in primary human hepatocytes.

Authors:  Marc Le Vee; Elodie Jouan; Amélie Moreau; Olivier Fardel
Journal:  Fundam Clin Pharmacol       Date:  2011-02       Impact factor: 2.748

6.  Differential regulation of hepatic transporters in the absence of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and nuclear factor-kappaB in two models of cholestasis.

Authors:  Andrew J Lickteig; Angela L Slitt; Melek C Arkan; Michael Karin; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2006-12-06       Impact factor: 3.922

7.  Gene expression analysis of membrane transport proteins in normal and lipopolysaccharide-inflamed rat dental pulp.

Authors:  Naoto Ohkura; Yoshimi Shigetani; Nagako Yoshiba; Kunihiko Yoshiba; Takashi Okiji
Journal:  J Endod       Date:  2012-03-27       Impact factor: 4.171

8.  Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6- and interferon-{gamma}-null mice.

Authors:  Beatrice A Nyagode; Choon-Myung Lee; Edward T Morgan
Journal:  J Pharmacol Exp Ther       Date:  2010-08-18       Impact factor: 4.030

9.  Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer.

Authors:  Edward T Morgan; Kerry B Goralski; Micheline Piquette-Miller; Kenneth W Renton; Graham R Robertson; Madhusudana R Chaluvadi; Kellie A Charles; Stephen J Clarke; Marina Kacevska; Christopher Liddle; Terrilyn A Richardson; Rohini Sharma; Christopher J Sinal
Journal:  Drug Metab Dispos       Date:  2008-02       Impact factor: 3.922

10.  Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease.

Authors:  Mario Congiu; Maurice L Mashford; John L Slavin; Paul V Desmond
Journal:  J Gastroenterol Hepatol       Date:  2009-06       Impact factor: 4.029

View more
  8 in total

Review 1.  The role of transporters in toxicity and disease.

Authors:  John D Schuetz; Peter W Swaan; Donald J Tweedie
Journal:  Drug Metab Dispos       Date:  2014-04       Impact factor: 3.922

2.  Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma.

Authors:  Elisa Herraez; Marta R Romero; Rocio I R Macias; Maria J Monte; Jose J G Marin
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

3.  Impact of Viral Inflammation on the Expression of Renal Drug Transporters in Pregnant Rats.

Authors:  Navaz Karimian Pour; Eliza R McColl; Micheline Piquette-Miller
Journal:  Pharmaceutics       Date:  2019-11-22       Impact factor: 6.321

4.  Downregulation of Renal MRPs Transporters in Acute Lymphoblastic Leukemia Mediated by the IL-6/STAT3/PXR Signaling Pathway.

Authors:  Yi Zheng; Wei Zhao; Yue Zhou; Ai-Qing Nie; Shang Chen; Meng-Meng Wang; Rui Yin; Bo-Hao Tang; Yue-E Wu; Fan Yang; Bin Du; Hai-Yan Shi; Xin-Mei Yang; Guo-Xiang Hao; Xiu-Li Guo; Qiu-Ju Han
Journal:  J Inflamm Res       Date:  2021-05-25

Review 5.  Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics.

Authors:  Nicole Moschny; Gudrun Hefner; Renate Grohmann; Gabriel Eckermann; Hannah B Maier; Johanna Seifert; Johannes Heck; Flverly Francis; Stefan Bleich; Sermin Toto; Catharina Meissner
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-27

6.  Repression of intestinal transporters and FXR-FGF15 signaling explains bile acids dysregulation in experimental colitis-associated colon cancer.

Authors:  Lijuan Cao; Yuan Che; Tuo Meng; Shanshan Deng; Jun Zhang; Min Zhao; Wanfeng Xu; Dandan Wang; Zhichen Pu; Guangji Wang; Haiping Hao
Journal:  Oncotarget       Date:  2017-06-28

Review 7.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

8.  Breast cancer resistance protein (Bcrp/Abcg2) is selectively modulated by lipopolysaccharide (LPS) in the mouse yolk sac.

Authors:  L M Martinelli; M W Reginatto; K N Fontes; C B V Andrade; V R S Monteiro; H R Gomes; F R C L Almeida; F F Bloise; S G Matthews; T M Ortiga-Carvalho; E Bloise
Journal:  Reprod Toxicol       Date:  2020-09-08       Impact factor: 3.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.